Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04987359 · ClinicalTrials.gov registry record · NA
A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer
A NA study of Neoplasm Malignant, sponsored by Pennington Biomedical Research Center.
- Active
- Registry status
- NA
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT04987359 is a NA study of Neoplasm Malignant that is active but no longer recruiting, run by Pennington Biomedical Research Center. The registered enrollment target is 54 participants, below the 283-participant average among 7 other Neoplasm Malignant trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04987359, a NA study of Neoplasm Malignant, is active but no longer recruiting, sponsored by Pennington Biomedical Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
To examine the efficacy of a 10-week multimodal lifestyle program, versus waitlist control, on cardiorespiratory fitness capacity and body weight in survivors of cancer.
Conditions Studied
Interventions
- BEHAVIORAL Multimodal Lifestyle Program
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-08-19 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04987359
The ClinicalTrials.gov registry entry for NCT04987359 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 7 other Neoplasm Malignant trials with a reported enrollment target (81% lower). The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasm Malignant appearing as the primary indexed condition, and to 1 intervention - of which Multimodal Lifestyle Program is the first listed.
NCT04987359 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT04987359 about?
NCT04987359 is a clinical study titled "A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer". To examine the efficacy of a 10-week multimodal lifestyle program, versus waitlist control, on cardiorespiratory fitness capacity and body weight in survivors of cancer.
What is the current status of trial NCT04987359?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2021-08-19. Estimated completion is 2025-12-31.
What conditions does trial NCT04987359 study?
This clinical trial studies the following conditions: Neoplasm Malignant.
What interventions are being tested in trial NCT04987359?
The interventions under investigation include: Multimodal Lifestyle Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04987359?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04987359 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
ACTIVE NOT RECRUITING · NA
-
AIMS Cancer Outcomes Study
RECRUITING
-
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
RECRUITING · Phase 2
-
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
ACTIVE NOT RECRUITING · Phase 2
-
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
ACTIVE NOT RECRUITING · Phase 1
-
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.